184 related articles for article (PubMed ID: 17356170)
21. X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids.
Lusher SJ; Raaijmakers HC; Vu-Pham D; Kazemier B; Bosch R; McGuire R; Azevedo R; Hamersma H; Dechering K; Oubrie A; van Duin M; de Vlieg J
J Biol Chem; 2012 Jun; 287(24):20333-43. PubMed ID: 22535964
[TBL] [Abstract][Full Text] [Related]
22. Novel progesterone receptor modulators with gene selective and context-dependent partial agonism.
Berrodin TJ; Jelinsky SA; Graciani N; Butera JA; Zhang Z; Nagpal S; Winneker RC; Yudt MR
Biochem Pharmacol; 2009 Jan; 77(2):204-15. PubMed ID: 19013437
[TBL] [Abstract][Full Text] [Related]
23. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor.
Zhang X; Jeyakumar M; Petukhov S; Bagchi MK
Mol Endocrinol; 1998 Apr; 12(4):513-24. PubMed ID: 9544987
[TBL] [Abstract][Full Text] [Related]
24. In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties.
Afhüppe W; Beekman JM; Otto C; Korr D; Hoffmann J; Fuhrmann U; Möller C
J Steroid Biochem Mol Biol; 2010 Mar; 119(1-2):45-55. PubMed ID: 20043998
[TBL] [Abstract][Full Text] [Related]
25. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata.
Chwalisz K; Larsen L; Mattia-Goldberg C; Edmonds A; Elger W; Winkel CA
Fertil Steril; 2007 Jun; 87(6):1399-412. PubMed ID: 17307170
[TBL] [Abstract][Full Text] [Related]
26. Differential role of progesterone receptor isoforms in the transcriptional regulation of human gonadotropin-releasing hormone I (GnRH I) receptor, GnRH I, and GnRH II.
An BS; Choi JH; Choi KC; Leung PC
J Clin Endocrinol Metab; 2005 Feb; 90(2):1106-13. PubMed ID: 15562029
[TBL] [Abstract][Full Text] [Related]
27. Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN.
Wilkens J; Williams AR; Chwalisz K; Han C; Cameron IT; Critchley HO
Hum Reprod; 2009 May; 24(5):1036-44. PubMed ID: 19176543
[TBL] [Abstract][Full Text] [Related]
28. Amino-terminal domain of TIF2 is involved in competing for corepressor binding to glucocorticoid and progesterone receptors.
Wang D; Wang Q; Awasthi S; Simons SS
Biochemistry; 2007 Jul; 46(27):8036-49. PubMed ID: 17571860
[TBL] [Abstract][Full Text] [Related]
29. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata.
Williams AR; Critchley HO; Osei J; Ingamells S; Cameron IT; Han C; Chwalisz K
Hum Reprod; 2007 Jun; 22(6):1696-704. PubMed ID: 17339234
[TBL] [Abstract][Full Text] [Related]
30. Next step in the development of mesoprogestins: the preclinical profile of EC313.
Błaszczak-Świątkiewicz K; Krupa A; Mnich E; Elger W; Oettel M; Nair H; Wierzbicki M; Sieroszewski P; Shaked Z
Front Endocrinol (Lausanne); 2023; 14():1201547. PubMed ID: 37766684
[TBL] [Abstract][Full Text] [Related]
31. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women.
Chwalisz K; Elger W; Stickler T; Mattia-Goldberg C; Larsen L
Hum Reprod; 2005 Apr; 20(4):1090-9. PubMed ID: 15665012
[TBL] [Abstract][Full Text] [Related]
32. Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.
Islam MS; Afrin S; Jones SI; Segars J
Endocr Rev; 2020 Oct; 41(5):. PubMed ID: 32365199
[TBL] [Abstract][Full Text] [Related]
33. Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones.
Havrilesky LJ; McMahon CP; Lobenhofer EK; Whitaker R; Marks JR; Berchuck A
J Soc Gynecol Investig; 2001; 8(2):104-13. PubMed ID: 11336882
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a novel mechanism of steroid receptor antagonism: WAY-255348 modulates progesterone receptor cellular localization and promoter interactions.
Yudt MR; Russo LA; Berrodin TJ; Jelinsky SA; Ellis D; Cohen JC; Cooch N; Haglund E; Unwalla RJ; Fensome A; Wrobel J; Zhang Z; Nagpal S; Winneker RC
Biochem Pharmacol; 2011 Dec; 82(11):1709-19. PubMed ID: 21854761
[TBL] [Abstract][Full Text] [Related]
35. Anti-estrogenic mechanism of unliganded progesterone receptor isoform B in breast cancer cells.
Zheng ZY; Zheng SM; Bay BH; Aw SE; C-L Lin V
Breast Cancer Res Treat; 2008 Jul; 110(1):111-25. PubMed ID: 17687644
[TBL] [Abstract][Full Text] [Related]
36. Determination of conformational changes in the progesterone receptor using ELISA-like assays.
Pullen MA; Laping N; Edwards R; Bray J
Steroids; 2006 Sep; 71(9):792-8. PubMed ID: 16784762
[TBL] [Abstract][Full Text] [Related]
37. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression.
Uchikawa J; Shiozawa T; Shih HC; Miyamoto T; Feng YZ; Kashima H; Oka K; Konishi I
Cancer; 2003 Nov; 98(10):2207-13. PubMed ID: 14601091
[TBL] [Abstract][Full Text] [Related]
38. A new generation of progesterone receptor modulators.
Winneker RC; Fensome A; Zhang P; Yudt MR; McComas CC; Unwalla RJ
Steroids; 2008 Aug; 73(7):689-701. PubMed ID: 18472121
[TBL] [Abstract][Full Text] [Related]
39. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.
Jackson TA; Richer JK; Bain DL; Takimoto GS; Tung L; Horwitz KB
Mol Endocrinol; 1997 Jun; 11(6):693-705. PubMed ID: 9171233
[TBL] [Abstract][Full Text] [Related]
40. Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors.
Petit-Topin I; Fay M; Resche-Rigon M; Ulmann A; Gainer E; Rafestin-Oblin ME; Fagart J
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():427-35. PubMed ID: 25204619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
